Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial.

[1]  R. Shaban,et al.  ‘The Australian Immunisation Handbook 8th Edition’. National Health and Medical Research Council, Australian Government. Canberra: Commonwealth of Australia; 2003. 350 pages, ISBN 0-642-82204-2 , 2015 .

[2]  M. Ng,et al.  Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events. , 2014, Vaccine.

[3]  S. Koernig,et al.  Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine. , 2014, Vaccine.

[4]  J. Wong,et al.  Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Robert Booy,et al.  Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses. , 2012, Vaccine.

[6]  B. Cowling,et al.  Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Bernstein,et al.  Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. , 2010, Vaccine.

[8]  R. Webby,et al.  Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. , 2010, The Journal of infectious diseases.

[9]  H. Kelly,et al.  Seasonal influenza vaccination and the risk of infection with pandemic influenza: a possible illustration of non-specific temporary immunity following infection. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[10]  Alberto Arnedo-Pena,et al.  Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. , 2010, Vaccine.

[11]  P. Orellano,et al.  Protection of trivalent inactivated influenza vaccine against hospitalizations among pandemic influenza A (H1N1) cases in Argentina. , 2010, Vaccine.

[12]  Christopher L. Perdue,et al.  Seasonal Influenza Vaccine and Protection against Pandemic (H1N1) 2009-Associated Illness among US Military Personnel , 2010, PloS one.

[13]  K. Subbarao,et al.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.

[14]  A. Cook,et al.  2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. , 2010, JAMA.

[15]  D. Earn,et al.  Pandemic (H1N1) 2009 Risk for Nurses after Trivalent Vaccination , 2010, Emerging infectious diseases.

[16]  Laura C. Rosella,et al.  Association between the 2008–09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring–Summer 2009: Four Observational Studies from Canada , 2010, PLoS medicine.

[17]  J. McVernon,et al.  Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. , 2010, JAMA.

[18]  Derek A T Cummings,et al.  Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. , 2009, The New England journal of medicine.

[19]  Víctor Hugo Borja-Aburto,et al.  Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis , 2009, The Lancet.

[20]  M. Greenberg,et al.  Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.

[21]  C. Reed,et al.  Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Libo Dong,et al.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.

[23]  L. Finelli,et al.  Emergence of a novel swine-origin influenza A (H1N1) virus in humans. , 2009, The New England journal of medicine.

[24]  J. McVernon,et al.  Safety and immunogenicity of an inactivated thimerosal‐free influenza vaccine in infants and children , 2009, Influenza and other respiratory viruses.

[25]  Eduardo Lazcano-Ponce,et al.  Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City , 2009, BMJ : British Medical Journal.

[26]  H. Kelly,et al.  Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[27]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Nicholas S. Kelley,et al.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[29]  L. Balluz,et al.  Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[30]  T. Popović,et al.  Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. , 2009, MMWR. Morbidity and mortality weekly report.